Weekly Report (March 22-28, 2024) on the First Tranch of Stellantis 2024 Share Buyback Program

Written by Customer Service on March 29, 2024. Posted in Public Companies.

Weekly Report (March 22-28, 2024) on the First Tranch of Stellantis 2024 Share Buyback Program AMSTERDAM, March 29, 2024 – Stellantis N.V. (“Stellantis” or the “Company”) announced today that pursuant to its First Tranche of the 2024 Share Buyback Program announced on February 28, 2024, covering up to €1 billion to be executed in the open market during the period between February 28, 2024 and June 5, 2024, it has repurchased the following common shares in the period between March 22 up to and including March 28, 2024: Date Number of Shares Repurchased Average Market Purchase Price in € per share Repurchased Volume in € (excluding fees) Venues 22-march-24 1 108 826 €26.9760 €29 911 719,75 MI 25-march-24 337 957 €27.0499 €9 141 692,09 MI 26-march-24 346 584 €26.6342 €9 230 992,66 MI Total 1 793 367 €26.9239 €48 284 404,50 Since...

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Written by Customer Service on March 29, 2024. Posted in Public Companies.

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on reversing aging in canines BALTIMORE, March 29, 2024 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and global animal health contract research, development and manufacturing organisation Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases...

Table Trac, Inc. Reports Year End Results for 2023

Written by Customer Service on March 29, 2024. Posted in Public Companies.

MINNETONKA, Minn., March 29, 2024 (GLOBE NEWSWIRE) — Table Trac, Inc. (OTCQX: TBTC), a developer and provider of casino information and management systems that automate and monitor the operations of casinos announced financial results for the year ended December 31, 2023. The 10-K can be found @ http://www.sec.gov Year End Highlights Record $7 Million in Gross Profit Gross Margin percentage exceeds 74% Record reoccurring revenue of $4.9 Million a 42% increase over the prior year Table Trac declared and paid three quarterly dividends of $0.01/share. The CasinoTrac system was installed in thirteen locations during 2023. At the end of 2023, the Company had casino management systems, table games management systems and ancillary products installed with 110 casino operators in over 300 casinos worldwide. Table Trac established an office/showroom...

Avalo Reports 2023 Financial Results and Provides Business Updates

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2023. “We are very excited about the acquisition of AVTX-009 and concurrent financing of up to $185 million, $115.6 million of which we received upfront. The progress we made in 2023 to strengthen our balance sheet helped enable these transactions. I am proud of the team’s efforts and continued dedication in executing...

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – Topline data from planned interim analysis of ongoing Phase 2 study in chronic migraine are expected to be announced in Q2 2024; On track to announce top-line data from the full study in Q3 2024 – – Announced private placement agreements for $15 million in aggregate principal amount of senior secured convertible notes – IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for...

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT Phase 1 trial ongoing for VIP943, a best-in-class anti-CD123 antibody-drug conjugate (ADC); preliminary data anticipated on or around the 2024 European Hematology Association (EHA) Annual Meeting; in addition, pharmacokinetic data will be shared at the 2024 American Association of Cancer Research (AACR) Annual Meeting Expected cash runway into early Q3 2024 PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter...

DEKUPLE – 2023 FULL-YEAR EARNINGS: further year of strong growth in line with the “Ambition 2025” plan

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

2023 FULL-YEAR EARNINGS: further year of strong growth in line with the “Ambition 2025” plan_____ Net sales: €200m (+10.2%) Gross margin: €161m (+11%) Net income (Group share): €12.4m, representing 7.7% of gross margin (+20 basis points) Proposed dividend: €1.04 per share “Ambition 2025”: becoming a European leader for data marketing Paris, 29 March 2024 (6:00pm) – ADLPartner, the parent company of the DÉKUPLE Group, a European cross-channel data marketing expert, is reporting its full-year earnings for 2023. Bertrand Laurioz, DÉKUPLE Chairman and CEO: “2023 was a very positive year for our Group. Following the economic crises that began in 2022 relating to energy, purchasing power and Ukraine, the global geopolitical situation was still very unstable, but the Group successfully resisted these new challenges. With the rapid...

Proactis SA – 18 months revenue 31 January 2024

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

Proactis SA Announces Financial Information for the year ended 31 January 2024 Paris – March 29, 2024 – Proactis SA (Euronext: PROAC), a leading provider of comprehensive spend management and business process collaboration solutions, today announces financial information for the year ended 31 Janvier 2024, in accordance with the “European Transparency Obligations Directive” financial disclosure requirements. Financial data in € million 18 months – Year ended 31 Jan 2024 12 months – Year ended 31 July 2022 % Change2023/ 2022(*) Consolidated Operationnal Revenue 11.3 9.8 15% SaaS (**) 9.4 7.9 20% Services 1.9 1.9 -4% Management fees 6.6 4.6 45% Consolidated Revenue 17.9 14.4 25% (unaudited...

Equasens: 2023 Annual Results

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

Villers-lès-Nancy, 29 March 2024 – 6:00 p.m. (CET) PRESS RELEASE 2023 Annual Results Annual results impacted by the overperformance at the end of 2022 and early 2023 driven by solutions introduced under the Ségur programme as well as an unfavourable economic climate Revenue: €219.7m, +2.6% Net Profit: €48.9m, +0.4% Net Profit attributable to Group shareholders: €47.0m, +1.4% The Current Operating Margin remains at a high level (25.4%) Dividend proposal for FY 2023: €1.25 per share (+9.2%) In €m 2021 2022 2023 Change2023/2022 Revenue 193.1 214.1 219.7 +2.6% Current Operating Income 50.5 56.8 55.8 -1.7% Net Profit* 41.2 48.7 48.9 +0.4% Net Profit attributable to the Group 39.1 46.4 47.0 +1.4% Basic earnings per share (in €) 2.6 3.09 3.13 +1.4% Current operating income (€m) 2022 reported basis 2023...

Edf: Changes in EDF’s business organisation and appointments to the EDF Group Executive Committee

Written by Customer Service on March 29, 2024. Posted in Public Companies.

Changes in EDF’s business organisation and appointments to the EDF Group Executive Committee The EDF Group is called upon to play a major role in the relaunching of a nuclear program. The new organisation of EDF’s nuclear business and of the Innovation, Corporate Responsibility and Strategy Directorate will come into effect on April 1st, 2024. This change is aimed at grouping expertise and skills into major specialisms, placing methods on an “industrial” footing to improve performance, and reinforcing cross-functional working within the company. From April 1st, EDF’s nuclear business will be organised into four directorates and one unit. This new organisation has resulted in a number of appointments: Xavier Ursat has been appointed Group Senior Executive Vice President with responsibility for the Strategy, Technologies, Innovation and...

Month: March 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice